Patent US4889808A successfully refreshed from Google Patents.
US4889808A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of enchancing t-PA and SCU-PA production
Assignee: Wyeth LLC
•
Filing: 1986-09-17
•
Granted: 1989-12-26
•
Expires: 2006-09-17
Abstract
Abstract Disclosed herein is a method of enhancing the production of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (SCU-PA) by normal human lung diploid fibroblast cells in a serum-free medium. The method comprises the addition of heparin (or low molecular weight heparin) and an endothelial cell growth factor to the culture medium.
Inventors
- 👤 Ruth Rappaport
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 17:03
CPC Classifications
C; C12; C12N; C12N5/00; C12N5/06; C12N5/0602; C12N9/00; C12N9/14; C12N9/48; C12N9/50; C12N9/64; C12N9/6421; C12N9/6424; C12N9/6456; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/726; A61K31/727; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1825; A61K45/00; A61K45/06; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948
Claims Analysis
Total Claims: 42
Claim 1
Independent Claim
47 words
A method of enhancing the production of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (SCU-PA) in normal human diploid lung fibroblast cell cultures in a serum-free medium comprising adding to said culture heparin or low molecular weight heparin and an endothelial cell growth factor.
Claim 2
Independent Claim
47 words
A method of enhancing the production of tissue plasminogen activator (t-PA) and single chain urokinase plasminogen activator (SCU-PA) in normal human diploid lung fibroblast cell cultures in a serum-free medium comprising adding to said culture heparin or low molecular weight heparin and an endothelial cell growth factor.
Claim 3
Dependent Claim
11 words
A method according to claim 1 in which heparin is used.
Claim 4
Dependent Claim
24 words
A method according to claim 1 in which the concentration of heparin or low molecular weight heparin is from 5 mcg/ml to 220 mcg/ml.
Claim 5
Dependent Claim
23 words
A method according to claim 1 in which the concentration of heparin or low molecular weight heparin is 30 mcg/ml to 100 mcg/ml.
Claim 6
Dependent Claim
17 words
A method according to claim 1 in which the standard endothelial cell growth factor (ECGF) is used.
Claim 7
Dependent Claim
20 words
A method according to claim 5 in which the concentration of the standard ECGF is 5 mcg/ml to 220 mcg/ml.
Claim 8
Dependent Claim
20 words
A method according to claim 5 in which the concentration of the standard ECGF is 25 mcg/ml to 60 mcg/ml.
Claim 9
Dependent Claim
16 words
A method according to claim 1 in which purified endothelial cell growth factor (p-ECGF) is used.
Claim 10
Dependent Claim
18 words
A method according to claim 8 in which the concentration of p-ECGF is 50 ng/ml to 500 ng/ml.
Claim 11
Dependent Claim
18 words
A method according to claim 8 in which the concentration of p-ECGF is 100 ng/ml to 300 ng/ml.
Claim 12
Dependent Claim
49 words
A method according to claim 1 in which the endothelial cell growth factor is selected from endothelial cell growth factor (ECGF), acidic brain-derived fibroblast growth factor (acidic FGF), bovine eye-derived growth factor-II (EDGF-II), α-heparin-binding growth factor (α-HGF), acidic hypothalmus-derived growth factor (acidic HDGF), and retina derived growth factor (RDGF).
Claim 13
Dependent Claim
24 words
A method according to claim 1 in which the normal human diploid lung fibroblast cell culture is selected from WI-38, MRC-5, IMR-90 and IMR-91.
Claim 14
Dependent Claim
18 words
A method according to claim 1 in which the normal human diploid lung fibroblast cell culture is WI-38.
Claim 15
Independent Claim
40 words
A method of enhancing the production of tissue plasminogen activator (t-PA) in normal human diploid lung fibroblast cell cultures in a serum-free medium comprising adding to said culture heparin or low molecular weight heparin and an endothelial cell growth factor.
Claim 16
Independent Claim
40 words
A method of enhancing the production of tissue plasminogen activator (t-PA) in normal human diploid lung fibroblast cell cultures in a serum-free medium comprising adding to said culture heparin or low molecular weight heparin and an endothelial cell growth factor.
Claim 17
Dependent Claim
11 words
A method according to claim 14 in which heparin is used.
Claim 18
Dependent Claim
24 words
A method according to claim 14 in which the concentration of heparin or low molecular weight heparin is from 5 mcg/ml to 220 mcg/ml.
Claim 19
Dependent Claim
23 words
A method according to claim 14 in which the concentration of heparin or low molecular weight heparin is 30 mcg/ml to 100 mcg/ml.
Claim 20
Dependent Claim
17 words
A method according to claim 14 in which the standard endothelial cell growth factor (ECGF) is used.
Claim 21
Dependent Claim
20 words
A method according to claim 18 in which the concentration of the standard ECGF is 5 mcg/ml to 220 mcg/ml.
Claim 22
Dependent Claim
20 words
A method according to claim 18 in which the concentration of the standard ECGF is 25 mcg/ml to 60 mcg/ml.
Claim 23
Dependent Claim
16 words
A method according to claim 14 in which purified endothelial cell growth factor (p-ECGF) is used.
Claim 24
Dependent Claim
18 words
A method according to claim 21 in which the concentration of p-ECGF is 50 ng/ml to 500 ng/ml.
Claim 25
Dependent Claim
18 words
A method according to claim 21 in which the concentration of p-ECGF is 100 ng/ml to 300 ng/ml.
Claim 26
Dependent Claim
49 words
A method according to claim 14 in which the endothelial cell growth factor is selected from endothelial cell growth factor (ECGF), acidic brain-derived fibroblast growth factor (acidic FGF), bovine eye-derived growt factor-II (EDGF-II), α-heparin-binding growth factor (α-HGF), acidic hypothalmus-derived growth factor (acidic HDGF), and retina derived growth factor (RDGF).
Claim 27
Dependent Claim
24 words
A method according to claim 14 in which the normal human diploid lung fibroblast cell culture is selected from WI-38, MRC-5, IMR-90 and IMR-91.
Claim 28
Dependent Claim
18 words
A method according to claim 14 in which the normal human diploid lung fibroblast cell culture is WI-38.
Claim 29
Independent Claim
42 words
A method of enhancing the production of single chain urokinase plasminogen activator (SCU-PA) in normal human diploid lung fibroblast cell cultures in a serum-free medium comprising adding to said culture heparin or low molecular weight heparin and an endothelial cell growth factor.
Claim 30
Independent Claim
42 words
A method of enhancing the production of single chain urokinase plasminogen activator (SCU-PA) in normal human diploid lung fibroblast cell cultures in a serum-free medium comprising adding to said culture heparin or low molecular weight heparin and an endothelial cell growth factor.
Claim 31
Dependent Claim
11 words
A method according to claim 27 in which heparin is used.
Claim 32
Dependent Claim
24 words
A method according to claim 27 in which the concentration of heparin or low molecular weight heparin is from 5 mcg/ml to 220 mcg/ml.
Claim 33
Dependent Claim
23 words
A method according to claim 27 in which the concentration of heparin or low molecular weight heparin is 30 mcg/ml to 100 mcg/ml.
Claim 34
Dependent Claim
17 words
A method according to claim 27 in which the standard endothelial cell growth factor (ECGF) is used.
Claim 35
Dependent Claim
20 words
A method according to claim 31 in which the concentration of the standard ECGF is 5 mcg/ml to 220 mcg/ml.
Claim 36
Dependent Claim
20 words
A method according to claim 31 in which the concentration of the standard ECGF is 25 mcg/ml to 60 mcg/ml.
Claim 37
Dependent Claim
16 words
A method according to claim 27 in which purified endothelial cell growth factor (p-ECGF) is used.
Claim 38
Dependent Claim
18 words
A method according to claim 34 in which the concentration of p-ECGF is 50 ng/ml to 500 ng/ml.
Claim 39
Dependent Claim
18 words
A method according to claim 34 in which the concentration of p-ECGF is 100 ng/ml to 300 ng/ml.
Claim 40
Dependent Claim
49 words
A method according to claim 27 in which the endothelial cell growth factor is selected from endothelial cell growth factor (ECGF), acidic brain-derived fibroblast growth factor (acidic FGF), bovine eye-derived growth factor-II (EDGF-II), α-heparin-binding growth factor (α-HGF), acidic hypothalmus-derived growth factor (acidic HDGF), and retina derived growth factor (RDGF).
Claim 41
Dependent Claim
24 words
A method according to claim 27 in which the normal human diploid lung fibroblast cell culture is selected from WI-38, MRC-5, IMR-90 an IMR-91.
Claim 42
Dependent Claim
18 words
A method according to claim 27 in which the normal human diploid lung fibroblast cell culture is WI-38.
References Cited (Backward Citations)
US4752603A
Cited
US4505893A
Cited
US4520107A
Cited
US4798796A
Cited
US4757005A
Cited
US4661453A
Cited
EP0251806A2
Cited
JPH01271987A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-12-25 | 1993-06-26 | 1993-12-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-12-25 | 1997-06-26 | 1997-12-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-12-25 | 2001-06-26 | 2001-12-26 | $7700.00 | Window Closed / Lapsed |